Back to Careers

Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1

Back to Careers

CIRM Awards Juvena a $3.9M TRAN1 Grant to Advance JUV-161 for Myotonic Dystrophy Type 1 (DM1)

Back to Careers

Juvena Therapeutics Interviewed– Embryonic Proteins for Tissue Regeneration- Jan 2020

Back to Careers

Juvena Therapeutics Listed as 1 of 3 Ground Breaking Longevity Startups

Back to Careers

CEO Hanadie Yousef’s Entrepreneurship Recognized by Spark at Stanford

Back to Careers

CEO Hanadie Yousef’s Most Recent Publication in Nature Medicine

Back to Careers

Antibody Can Protect Brains From the Ageing Effects of Old Blood